Don’t need to I did further research into these types of peptides in this class. All showed safety, pre clinical success but could never show not 1 percent improvement in humans. It’s why the CEO in every interview states that any percentage of success is important even if it’s 1 percent. Even though preclinical success was strong, she knows every peptide in this drug class has failed before and it’s not a reflection of the outcome.
If AGN was a new drug class first of its kind having this safety and pre clinical success I would be more optimistic and certain it would most likely work to hold beyond safety and pre clinical studies coming up because it means that it’s the first of its kind. But also it’s a peptide and this type of drugs has many flaws and it’s why only around 100 peptides have been approved by the FDA since 1921. In it for the period ahead
- Forums
- ASX - By Stock
- AGN
- AGN Media thread
AGN Media thread, page-187
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
|
|||||
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M |
Open | High | Low | Value | Volume |
78.0¢ | 80.5¢ | 78.0¢ | $71.40K | 90.43K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 78.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
80.5¢ | 2444 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 0.785 |
1 | 10000 | 0.780 |
2 | 25477 | 0.775 |
2 | 16000 | 0.770 |
2 | 58000 | 0.760 |
Price($) | Vol. | No. |
---|---|---|
0.805 | 2444 | 1 |
0.830 | 2298 | 2 |
0.850 | 10650 | 2 |
0.860 | 12500 | 1 |
0.865 | 14194 | 2 |
Last trade - 15.55pm 23/08/2024 (20 minute delay) ? |
AGN (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online